Johnson & Johnson Expands Cell Therapy Portfolio with Cellular Biomedicine Group Deal
核心洞察
Johnson & Johnson has acquired rights to two experimental CAR-T therapies from Cellular Biomedicine Group (搜索) for $245 million upfront, expanding its presence in cell therapy.
The acquired therapies target recurrent diffuse large B cell lymphoma (搜索) (DLBCL (搜索)) and follicular lymphoma (搜索), utilizing bispecific approaches to target CD19 (搜索), CD20 (搜索), or CD20 alone.
This deal builds on J&J's success with Carvykti, a CAR-T therapy for multiple myeloma (搜索), and includes potential milestone payments and royalties on net sales.
Johnson & Johnson (J&J) has significantly expanded its cell therapy portfolio by acquiring rights to two experimental CAR-T therapies from Cellular Biomedicine Group (搜索) (CBMG) for an upfront payment of $245 million. This strategic move aims to build upon J&J's success with Carvykti, a CAR-T treatment for multiple myeloma (搜索), and further solidify its position in the rapidly evolving field of cell therapy.
The deal grants J&J access to two CAR-T therapies currently in early-phase development for B-cell lymphomas. One therapy is undergoing Phase 1 testing, while the other is slated to begin human studies later this year. These therapies represent next-generation approaches in cancer treatment, with one being a bispecific treatment designed to target both CD19 (搜索) and CD20 (搜索), two distinct targets found on the surface of cancerous cells. The other candidate targets CD20 and is being developed as a treatment for follicular lymphoma (搜索).
Targeting B-Cell Lymphomas
The more advanced of the two programs is a "bispecific" treatment, reprogramming a patient’s immune cells to find two different targets — CD19 (搜索) and CD20 (搜索) — found on the surface of cancerous cells. The other candidate targets CD20 and is being developed as a treatment for follicular lymphoma (搜索). Diffuse large B-cell lymphoma (DLBCL (搜索)) is the most common form of non-Hodgkin lymphoma, representing a significant unmet medical need. Follicular lymphoma is another common subtype of non-Hodgkin lymphoma. These lymphomas are characterized by the uncontrolled growth of B cells, a type of white blood cell responsible for producing antibodies.
Financial Terms and Strategic Implications
In addition to the initial $245 million payment, the agreement includes unspecified milestone payments and royalties on net sales if the treatments are approved. While the deal currently excludes China, J&J retains the option to acquire rights in that market as well. This agreement marks a significant step for Cellular Biomedicine Group (搜索), which was one of the first pure-play biotechnology companies from China to list on the Nasdaq stock exchange before going private in 2021. Prior to this deal, CBMG partnered with Novartis to supply Kymriah, the first U.S.-approved CAR-T cell therapy, in China.
This strategic alliance is expected to close in the second quarter of 2024, pending customary closing conditions. The acquisition underscores Johnson & Johnson's commitment to innovation in cell therapy and its ambition to develop next-generation treatments for hematologic malignancies.